Age, cancer and the risk of venous thromboembolism

Critical Reviews in Oncology/Hematology

Volumn 55, Issue 3, 2005, Pages 207-212

  Fimognari, Filippo Luca ^a   Repetto, Lazzaro ^b   Moro, Leo ^a   Gianni, Walter ^b   Incalzi, Raffaele Antonelli ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b INRCA   (Italy)

Author keywords

Aging; Cancer; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; COUMARIN; DALTEPARIN; ENOXAPARIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MITOMYCIN; NADROPARIN; TAMOXIFEN; WARFARIN;

ABDOMINAL SURGERY; AGING; ARTICLE; BACKACHE; BLEEDING; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CENTRAL VENOUS CATHETER; COLORECTAL CANCER; DISEASE ASSOCIATION; FRAGILITY FRACTURE; HUMAN; PELVIS SURGERY; POSTMENOPAUSE; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

EID: 24044503338     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.04.011     Document Type: Review

References (44)

1. L. Rodger, and M.D. Bick Cancer-associated thrombosis N Engl J Med 349 2003 109 111
2. S. Sallah, J.Y. Wan, and N.P. Nguyen Venous thrombosis in patients with solid tumors: determination of frequency and characteristics Thromb Haemost 87 2002 575 579
3. P. Prandoni, A. Piccioli, and A. Girolami Cancer and venous thromboembolism: an overview Haematologica 84 1999 437 445
4. J.A. Heit, M.D. Silverstein, and D.N. Mohr The epidemiology of venous thromboembolism in the community Thromb Haemost 86 2001 452 463
5. P.J. Hamilton, P.J.M. Allardice, D. Ogston, A.A. Dawson, and A.S. Douglas The effect of age upon the coagulation system J Clin Pathol 27 1974 980 982
6. D. Mari, P.M. Mannucci, and R. Coppola Hypercoagulability in centenarians: the paradox of successful aging Blood 85 1995 3144 3149
7. R. Alikhan, A.T. Cohen, and S. Combe Risk factors for venous thromboembolism in hospitalized patients with acute medical illness. Analysis of the MEDENOX Study Arch Intern Med 164 2004 963 968
8. J.A. Heit, D.N. Mohr, and M.D. Silverstein Predictors of recurrence after deep vein thrombosis and pulmonary embolism Arch Intern Med 160 2000 761 768
9. Per-Olof Hansson, J. Sorbo, and H. Eriksson Recurrent venous thromboembolism after deep vein thrombosis. Incidence and risk factors Arch Intern Med 160 2000 769 774
10. P. Prandoni, A.W.A. Lensing, and H.R. Buller Deep vein thrombosis and the incidence of subsequent symptomatic cancer N Engl J Med 327 1992 1128 1133
11. J.A. Baron, G. Gridley, E. Weiderpass, O. Nyren, and M. Linet Venous thromboembolism and cancer Lancet 351 1998 1077 1080
12. T.H. Sorensen, L. Mellemkjaer, F.H. Steffensen, J. Olsen, and G.L. Nielsen The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism N Engl J Med 338 1998 1169 1173
13. R.J. Goldberg, M. Seneff, and J.M. Gore Occult malignant neoplasm in patients with deep venous thrombosis Arch Intern Med 147 1987 251 253
14. N. Levitan, A. Dowlati, and S.C. Remick Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data Medicine (Baltimore) 78 1999 285 291
15. H.M. Otten, J. Mathijssen, and H. ten Cate Symptomatic venous thromboembolism in cancer patients treated with chemotherapy Arch Intern Med 164 2004 190 194
16. M.N. Levine, M. Gent, and J. Hirsh The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer N Engl J Med 318 1988 404 407
17. T. Saphner, D.C. Tormey, and R. Gray Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer J Clin Oncol 9 1991 286 294
18. K.I. Pritchard, A.H. Paterson, N.A. Paul, B. Zee, S. Fine, and J. Pater Increased thromboembolic complications with concurrent Tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer J Clin Oncol 14 1996 2731 2737
19. B. Fischer, J. Costantino, and C. Redmond A randomized clinical trial evaluating Tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors N Engl J Med 320 1989 479 484
20. M. Levine, J. Hirsch, and M. Gent Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV Breast cancer Lancet 343 1994 886 889
21. M. Verso, and G. Agnelli Venous thromboembolism associated with long-term use of central venous catheters in cancer patients J Clin Oncol 21 2003 3665 3675
22. M.M. Bern, J.J. Lokich, and S.R. Wallach Very low dose of warfarin can prevent thrombosis in central venous catheters Ann Intern Med 112 1990 423 428
23. M. Monreal, A. Alastrue, and M. Rull Upper extremity deep venous thrombosis in cancer patients with venous acces devices Prophylaxis with a low molecular weight heparin (Fragmin) Thromb Haemost 75 1996 251 253
24. P. Mismetti, D. Mille, and S. Laporte Low-molecular weight heparin (nadroparin) and very low dose of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial Haematologica 88 2003 67 73
25. W. Geerts, G.F. Pineo, and J.A. Heit Prevention of venous thromboembolism. Seventh ACCP Consensus Conference on Antithrombotic Therapy Chest 126 2004 338S 400S
26. D. Bergqvist Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment Brit J Surg 84 1997 1099 1103
27. D. Bergqvist, U.S. Burmark, and P.A. Flordal Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients Brit J Surg 82 1995 496 501
28. D. Bergqvist, G. Agnelli, and A. Cohen ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer N Engl J Med 346 2002 975 980
29. M. Levine, M. Gent, and J. Hirsh A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis N Engl J Med 334 1996 677 681
30. M.W. Koopman, P. Prandoni, and F. Piovella Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home N Engl J Med 334 1996 682 687
31. The Columbus Investigators Low molecular weight heparin in the treatment of patients with venous thromboembolism N Engl J Med 337 1997 657 662
32. B.A. Hutten, M.H. Prins, M. Gent, J.G.P. Tijssen, and H.R. Buller Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis J Clin Oncol 18 2000 3078 3083
33. G. Palareti, C. Legnani, and A. Lee A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy Thromb Haemost 84 2000 805 810
34. P. Prandoni, A.W.A. Lensing, and A. Piccioli Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 2002 3484 3488
35. J.H. Gurwitz, J. Avorn, D. Ross-Degnan, I. Choodnovskiy, and J. Ansell Aging and the anticoagulant response to warfarin therapy Ann Int Med 116 1992 901 904
36. G. Palareti, N. Leali, and S. Coccheri Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Lancet 348 1996 423 428
37. G. Meyer, Z. Marjanovic, and J. Valcke Comparison of low molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer Arch Intern Med 162 2002 1729 1735
38. F. Veiga, A. Escriba, and M.P. Maluenda Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long term treatment of deep venous thrombosis in the elderly: a randomized trial Thromb Haemost 84 2000 559 564
39. A.Y.Y. Lee, M.N. Levine, and R. Baker Low molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 2003 146 153
40. J. Hirsh, and R. Raschke Heparin and low-molecular weight heparin. The Seventh ACCP conference on antithrombotic and thrombolytic therapy Chest 126 2004 188S 203S
41. V. Siguret, E. Pautas, and M. Fevrier Elderly patients treated with tinzaparin administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-Iia activities over 10 days Thromb Haemost 84 2000 800 804
42. P. Mismetti, S. Laporte-Simitsidis, and C. Navarro Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin) Thromb Haemost 79 1998 1162 1165
43. S.L. Chow, K. Zammit, K. West, M. Dannenhoffer, and S. Lopez-Candales Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin J Clin Pharmacol 43 2003 586 590
44. G.J. Sanderink, C.G. Guimart, M.L. Ozoux, N.U. Jariwala, U.A. Shukla, and B.X. Boutouyrie Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment Thromb Res 105 2002 225 231